President Obama Pushes BRAIN Initiative Forward
|
By LabMedica International staff writers Posted on 09 Apr 2013 |
In his State of the Union address, US President Obama outlined his strategy for creating jobs and building a growing, flourishing middle class by making an historic investment in medical research and development.
“If we want to make the best products, we also have to invest in the best ideas... Every dollar we invested to map the human genome returned USD 140 to our economy... Today, our scientists are mapping the human brain to unlock the answers to Alzheimer’s… Now is not the time to gut these job-creating investments in science and innovation. Now is the time to reach a level of research and development not seen since the height of the space race,” stated President Barack Obama, in the 2013 State of the Union address.
On April 2, 2012, at the White House, the President revealed an intrepid new research initiative designed to transform understanding of the human brain. Initiated with about USD 100 million in the President’s Fiscal Year 2014 Budget, the BRAIN (Brain Research through Advancing Innovative Neurotechnologies) Initiative’s goal to help researchers find new ways to treat, cure, and even prevent brain disorders, such as epilepsy, Alzheimer’s disease, and traumatic brain injury.
The BRAIN Initiative is designed to hasten the development and application of new technologies that will enable researchers to produce dynamic pictures of the brain that show how individual brain cells and complex neural circuits interact at the speed of thought. These technologies will create new ways to examine how the brain records, processes, uses, stores, retrieves vast quantities of information, and provide insights into the complex ties between behavior and brain function.
This initiative is one of the Administration’s “Grand Challenges” goals that require new developments in science and technology. In his address, the President called on research universities, companies, research foundations, and philanthropists to join with him in identifying and pursuing the Grand Challenges of the 21st century.
The BRAIN Initiative includes: major investments to jumpstart the effort: The US National Institutes of Health (NIH; Bethesda, MD, USA), the Defense Advanced Research Projects Agency (DARPA; Arlington, VA, USA) , and the US National Science Foundation (Arlington, VA, USA) will support approximately USD 100 million in research beginning in FY 2014. Strong academic leadership: The NIH will establish a high-level working group cochaired by Dr. Cornelia Bargmann (The Rockefeller University; New York, NY, USA) and Dr. William Newsome (Stanford University; Stanford, CA, USA) to clarify detailed scientific goals for the NIH’s investment, and to develop a multiyear scientific plan for achieving these goals, including timetables, milestones, and cost estimates.
In the 10 years alone, scientists have made a number of landmark discoveries that now create the opportunity to gain further knowledge of the brain, including the sequencing of the human genome, the increasing resolution of imaging technologies, the development of new tools for mapping neuronal connections, and the expansion of nanoscience. These innovations have offered a chance for unprecedented collaboration and discovery across scientific fields. For instance, by combining sophisticated genetic and optical technologies, scientists can now use pulses of light to determine how specific cell activities in the brain affect behavior. Moreover, through the integration of neuroscience and physics, researchers can now use high-resolution imaging technologies to observe how the brain is structurally and functionally connected in living humans.
Whereas these technologic contributions have substantially added to expanding knowledge of the brain, significant breakthroughs in how physicians treat neurologic and psychiatric disease will require a new generation of applications to enable researchers to map signals from brain cells in much greater numbers and at even faster speeds. This cannot presently be accomplished, but great potential for developing such technologies lies at the crossroads of imaging, nanoscience, engineering, informatics, and other rapidly budding fields of science and engineering.
Related Links:
US National Institutes of Health
US Defense Advanced Research Projects Agency
US National Science Foundation
“If we want to make the best products, we also have to invest in the best ideas... Every dollar we invested to map the human genome returned USD 140 to our economy... Today, our scientists are mapping the human brain to unlock the answers to Alzheimer’s… Now is not the time to gut these job-creating investments in science and innovation. Now is the time to reach a level of research and development not seen since the height of the space race,” stated President Barack Obama, in the 2013 State of the Union address.
On April 2, 2012, at the White House, the President revealed an intrepid new research initiative designed to transform understanding of the human brain. Initiated with about USD 100 million in the President’s Fiscal Year 2014 Budget, the BRAIN (Brain Research through Advancing Innovative Neurotechnologies) Initiative’s goal to help researchers find new ways to treat, cure, and even prevent brain disorders, such as epilepsy, Alzheimer’s disease, and traumatic brain injury.
The BRAIN Initiative is designed to hasten the development and application of new technologies that will enable researchers to produce dynamic pictures of the brain that show how individual brain cells and complex neural circuits interact at the speed of thought. These technologies will create new ways to examine how the brain records, processes, uses, stores, retrieves vast quantities of information, and provide insights into the complex ties between behavior and brain function.
This initiative is one of the Administration’s “Grand Challenges” goals that require new developments in science and technology. In his address, the President called on research universities, companies, research foundations, and philanthropists to join with him in identifying and pursuing the Grand Challenges of the 21st century.
The BRAIN Initiative includes: major investments to jumpstart the effort: The US National Institutes of Health (NIH; Bethesda, MD, USA), the Defense Advanced Research Projects Agency (DARPA; Arlington, VA, USA) , and the US National Science Foundation (Arlington, VA, USA) will support approximately USD 100 million in research beginning in FY 2014. Strong academic leadership: The NIH will establish a high-level working group cochaired by Dr. Cornelia Bargmann (The Rockefeller University; New York, NY, USA) and Dr. William Newsome (Stanford University; Stanford, CA, USA) to clarify detailed scientific goals for the NIH’s investment, and to develop a multiyear scientific plan for achieving these goals, including timetables, milestones, and cost estimates.
In the 10 years alone, scientists have made a number of landmark discoveries that now create the opportunity to gain further knowledge of the brain, including the sequencing of the human genome, the increasing resolution of imaging technologies, the development of new tools for mapping neuronal connections, and the expansion of nanoscience. These innovations have offered a chance for unprecedented collaboration and discovery across scientific fields. For instance, by combining sophisticated genetic and optical technologies, scientists can now use pulses of light to determine how specific cell activities in the brain affect behavior. Moreover, through the integration of neuroscience and physics, researchers can now use high-resolution imaging technologies to observe how the brain is structurally and functionally connected in living humans.
Whereas these technologic contributions have substantially added to expanding knowledge of the brain, significant breakthroughs in how physicians treat neurologic and psychiatric disease will require a new generation of applications to enable researchers to map signals from brain cells in much greater numbers and at even faster speeds. This cannot presently be accomplished, but great potential for developing such technologies lies at the crossroads of imaging, nanoscience, engineering, informatics, and other rapidly budding fields of science and engineering.
Related Links:
US National Institutes of Health
US Defense Advanced Research Projects Agency
US National Science Foundation
Latest BioResearch News
- Lung Cancer Study Reveals Cellular Program Behind Therapy Resistance
- Tumor Genome Marker May Predict Treatment Benefit in Pediatric Cancers
- Lysosomal Gene Defect Linked to Severe Childhood Brain Disorders
- Genetic Testing Identifies Greater Inherited Sudden Cardiac Arrest Risk in Younger Individuals
- Hidden 'Jumping Gene' Variant Linked to Higher Pancreatic Cancer Risk
- Common White Blood Cells Produce Schizophrenia-Linked Protein
- Nanopore Method Captures RNA Folding at Single-Molecule Resolution
- Tumor Microenvironment Marker Linked to Worse Survival in Solid Tumors
- Hidden Immune Gene Defect May Explain Kaposi Sarcoma Susceptibility
- Genetic Markers May Help Predict Amputation Risk in Peripheral Artery Disease
- Gene Signature Shows Promise for Depression Biomarker Testing
- AI-Driven Tumor Profiling Initiative Targets Precision Therapy Development
- Researchers Map Protein and Glycosylation Across 15 Human Body Fluids
- Telomere Length Abnormalities Linked to Lymphoma Development
- Biomarker Signals Chemotherapy Resistance in Relapsed Small Cell Lung Cancer
- Inflammatory Gene Signature Links Metabolic Disease to Pancreatic Cancer Recurrence
Channels
Clinical Chemistry
view channel
Urine-Based Test Shows Promise for Autism Screening in Children
Autism spectrum disorder (ASD) is commonly diagnosed through behavioral assessments, which can involve long waits that delay intervention. Earlier identification is linked to better developmental outcomes,... Read more
Liquid Biopsy Biomarkers May Improve Childhood Epilepsy Diagnosis
Childhood epilepsy remains a major neurological disorder with unmet needs for accurate, non-invasive biomarkers, as conventional tests such as electroencephalography and neuroimaging can have limited sensitivity... Read moreMolecular Diagnostics
view channel
Updated Guidance Prioritizes Stool-Based Colorectal Cancer Screening Tests
Colorectal cancer is the second-leading cause of cancer death in the United States and claimed an estimated 55,000 lives in 2026. Incidence is rising among adults younger than 50, even as overall mortality... Read more
Digital PCR Assays Support Surveillance of Bundibugyo Ebolavirus Outbreak
QIAGEN (Venlo, Netherlands) has introduced two custom-designed research-use-only (RUO) QIAcuity dPCR assays to support infectious disease research and surveillance connected to the Bundibugyo ebolavirus outbreak.... Read more
Blood-Based Proteomic Test May Predict Treatment Response in Non-Small Cell Lung Cancer
Lung cancer remains the leading cause of cancer death, with non-small cell lung cancer (NSCLC) accounting for most cases. Treatment decisions are often made without a clear indication of how a patient... Read moreHematology
view channel
Next-Generation Hematology Platform Streamlines High-Complexity Lab Workflows
Sysmex America (Chicago, IL, USA) has introduced the next generation XR-Series, centered on the XR-10 Automated Hematology Module for high-complexity laboratories. The platform builds on the widely used... Read more
Blood Eosinophil Count May Predict Cancer Immunotherapy Response and Toxicity
Immune checkpoint inhibitors have improved outcomes across many cancers, yet only a subset of patients derive durable benefit and biomarkers to guide treatment remain limited. Eosinophils, best known for... Read moreImmunology
view channel
Metabolic Biomarker Distinguishes Latent from Active Tuberculosis and Tracks Treatment Response
Tuberculosis (TB) remains the world’s leading infectious killer, with 10.8 million cases and 1.25 million deaths recorded globally in 2023. Yet many infected individuals never develop active disease, underscoring... Read more
Immune Enzyme Linked to Treatment-Resistant Inflammatory Bowel Disease
Inflammatory bowel disease (IBD) affects nearly 3 million people in the United States and its prevalence continues to rise. Medications that target tumor necrosis factor (TNF)-alpha are widely used, but... Read moreMicrobiology
view channel
Gut Microbiome Signatures Help Identify Risk of IBD Progression
Inflammatory bowel disease (IBD), encompassing Crohn’s disease and ulcerative colitis, is a chronic relapsing inflammatory disorder of the gastrointestinal tract with highly variable outcomes.... Read more
FDA-Cleared Gastrointestinal Panel Detects 24 Pathogen Targets
Clinical guidelines support testing based on patient presentation in suspected gastrointestinal infections, yet available technologies have often forced laboratories to choose between panels that are too... Read morePathology
view channel
AI-Powered Atlas Maps Immune Structures Linked to Cancer Outcomes
Tertiary lymphoid structures are emerging as important indicators of antitumor immunity, but their heterogeneity and spatial context within tumors remain difficult to capture through routine diagnostics.... Read more
AI Tool Extracts Immune Signals from Biopsy to Inform Myeloma Therapy
Multiple myeloma is a bone marrow malignancy in which patients can respond very differently to the same treatments, making initial therapy decisions difficult. Clinicians must choose among options such... Read moreTechnology
view channel
Mailed Screening Kits Help Reduce Colorectal Cancer Screening Gaps
Colorectal cancer screening is a longstanding preventive priority, yet participation and follow-up remain uneven across patient groups. Safety‑net primary care settings often face barriers that limit screening... Read more
Algorithm Panel Aids Liver Fibrosis Assessment and Liver Cancer Surveillance
Chronic liver disease is common and often progresses silently, increasing the risk of cirrhosis and hepatocellular carcinoma when not detected early. With an estimated 1.5 billion people affected worldwide... Read moreIndustry
view channelWerfen and Oxford Nanopore Collaborate on Transplant Assay Development
Werfen (Barcelona, Spain), a global specialized diagnostics company, has announced a strategic collaboration with Oxford Nanopore Technologies (Oxford, UK), which develops nanopore-based sequencing technology,... Read more








